Clin2
NCT05795465Possibly a fitRecruiting

Study drug for people with acute respiratory distress syndrome

Respiratory Distress Syndrome, Acute

Part of Lungs & breathing clinical trials.

This Phase 2 trial tests GEn-1124 to see if it can improve outcomes in people with acute respiratory distress syndrome (ARDS). You may be eligible if the study drug can be started very soon after ARDS is diagnosed and if you meet the safety and health requirements.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
52 people
Ages
18 years to 85 years
Study type
Interventional

Who can take part

  • Be an adult age 18 to 85
  • Start the study treatment as early as possible after ARDS is diagnosed using the ARDS 2023 definition
  • Be able to give informed consent (or have a legal process for consent)
  • Use acceptable birth control if there is any chance of pregnancy
  • Not be pregnant or breastfeeding

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06703073Recruiting· Phase 2
Testing new treatments for acute respiratory distress syndrome (ARDS)

This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.

Birmingham, Alabama
NCT06640777Not yet recruiting· Phase 3
Testing a new drug for severe lung injury

This trial tests a new drug called LEAF-4L6715 to see if it helps people with severe acute respiratory distress syndrome (ARDS), a serious lung condition. If you are on a breathing machine and meet the criteria below, you may be able to join.

Paris, Paris
NCT07208591Recruiting· Phase 3
Test of an experimental drug for severe viral lung infection (ARDS)

This study tests an experimental drug (STSA-1002) for people with severe breathing problems caused by a viral infection. It aims to see if the drug can help improve oxygen levels and reduce the need for a breathing machine.

Beijing, Beijing Municipality
NCT05947955Recruiting· Phase 2
Study drug for infection-related lung failure in adults

This Phase 2 trial tests Rhu-pGSN in adults with acute respiratory distress syndrome (ARDS) caused by an infection. If you qualify, the study may help determine whether the drug improves outcomes in this short-term, life-threatening lung condition.

Los Angeles, California
NCT05497401Not yet recruiting· Phase 3
Test stem-cell based treatment for adults with ARDS

This Phase 3 study tests whether an allogeneic “MesenCure” therapy can improve outcomes in adults with ARDS (a serious lung injury). It aims to see if the treatment helps patients recover better than standard care.

NCT07186140Not yet recruiting
Acute respiratory distress syndrome (ARDS) study: treatments and outcomes

This trial observes the symptoms, treatments, and recovery of patients with acute respiratory distress syndrome (ARDS), a serious lung condition. It aims to learn more about how different types of breathing support affect outcomes.

Seoul

Hear when a new Respiratory Distress Syndrome, Acute trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.